Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-866949 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2012
At a glance
- Drugs BMS 866949 (Primary)
- Indications Depressive disorders
- Focus Adverse reactions
- 26 Mar 2012 Actual patient number (47) added as reported by ClinicalTrials.gov.
- 26 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Dec 2011 Planned end date changed from 1 Oct 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.